Hims & Hers Health and Novo Nordisk have resolved one of the pharmaceutical industry's most combative recent legal battles, announcing a collaboration that will place the Danish giant's branded obesity medicines at the centre of the American telehealth company's weight-loss offering.
Shares in Hims & Hers jumped nearly 50 per cent in premarket trading on Monday before carrying those gains through the session, according to MarketWatch and CNBC, as investors welcomed the resolution of a dispute that had weighed on the company's strategic outlook and cast a legal shadow over its compounded weight-loss drug business.
Under the terms of the agreement, Novo Nordisk will sell its branded medicines, including Wegovy and Ozempic, through the Hims & Hers platform. In exchange, Novo Nordisk dropped its patent-infringement case against the telehealth provider, which had centred on Hims & Hers offering compounded versions of semaglutide-based weight-loss drugs. The Wall Street Journal and AP News confirmed the broad terms of the collaboration.
Hims & Hers characterised the arrangement as a strategic shift for its US weight-loss business, according to a statement carried by its investor relations division. The company had previously built a notable presence in the market for compounded obesity drugs, a category that sits in a legally and regulatorily contested space, making the pivot to distributing Novo's branded products a significant change in commercial direction.
The deal marks a striking reversal in the relationship between the two companies. Bloomberg described the agreement as one that ends what it called a public feud, while Barron's noted the surprising twist in what had been a protracted and adversarial standoff. The partnership effectively transforms Novo Nordisk from a litigant into a distribution partner for one of the United States' most prominent telehealth platforms.
Citi moved to upgrade its view on Hims & Hers following the announcement, according to Seeking Alpha, reflecting a reassessment of the company's prospects now that the legal overhang has been removed and a formal channel for branded obesity drug sales has been established.
The agreement arrives at a moment of intense commercial competition in the obesity drug market, where Novo Nordisk and its rivals are seeking to broaden patient access to their medicines while managing relationships with a fast-growing cohort of digital health companies that have built businesses partly around lower-cost alternatives. For Novo Nordisk, securing distribution through Hims & Hers offers access to the platform's established patient base, while neutralising a company that had been publicly at odds with its intellectual property strategy.
